Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab-Reference-Cited by-同舟云学术

Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab

Published:2015-09-08 Issue:5 Volume:98 Page:542-550
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Vermeer NS¹²,Straus SMJM²³,Mantel-Teeuwisse AK¹,Hidalgo-Simon A⁴,Egberts ACG¹⁵,Leufkens HGM¹²,De Bruin ML¹²

Affiliation:

1. Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology; Utrecht University; Utrecht The Netherlands

2. Medicines Evaluation Board; Utrecht The Netherlands

3. Medical Informatics; Erasmus Medical Center; Rotterdam The Netherlands

4. European Medicines Agency; London United Kingdom

5. Department of Clinical Pharmacy; University Medical Center Utrecht; Utrecht The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference42 articles.

1. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis;Tan;Lancet Neurol.,2010

2. Progressive multifocal leukoencephalopathy;Brooks;Neurol. Clin.,1984

3. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease;Astrom;Brain,1958

4. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases;Molloy;Arthritis Rheum.,2009

5. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study;Engsig;J. Infect. Dis.,2009

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic;British Journal of Dermatology;2022-12-01

2. Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study;Journal of Clinical Neuromuscular Disease;2022-09

3. Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database;Frontiers in Pharmacology;2022-02-23

4. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis;Multiple Sclerosis and Related Disorders;2020-04

5. Statistical Practices of Safety Monitoring: An Industry Survey;Therapeutic Innovation & Regulatory Science;2019-05